▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #146 by analyst upside · 2026-11-13
AEON
AEON Biopharma, Inc.
Healthcare · Market Cap $11M · P/E 0x
ANALYST PRICE TARGET
+1046.8%
implied upside to consensus target
Current Price $0.16
Consensus Target $1.82
Bull Target $2.1
Bear Target $1.2
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
4
Hold
0
Sell
0
52-Week Low $0.13
52-Week High $1.45
YTD Return -85.7%
FUNDAMENTALS
Market Cap $11M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-4.39
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.13
52-Week High $1.45
Current Price $0.16
Bear Target $1.2
Bull Target $2.1
● Now $0.16 ● Target $1.82
TRADING DATA
Avg Volume 7.7M
YTD Return -85.7%
Analyst Count 5
Consensus Buy
Upside to Target +1046.8%
Last Updated 2026-11-13

ANALYST SUMMARY

AEON Biopharma, Inc. (AEON) is currently trading at $0.16 with a Wall Street consensus price target of $1.82, implying potential upside of 1046.8% over the next 12 months. 5 analysts currently cover AEON, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $2.1, while the most cautious has a target of $1.2.

AEON operates in the Healthcare sector with a market capitalisation of $11M. The stock is down 85.7% year-to-date and is currently trading near the lower end of its 52-week range of $0.13 – $1.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ETST +956.0%
Earth Science Tech, Inc.
$27M · P/E 9.5x · Hold
DWTX +1150.0%
Dogwood Therapeutics, Inc.
$43M · P/E 0.1x · Strong Buy
NCEL +755.0%
NewcelX Ltd.
$16M · P/E 5.2x · Hold
VXRT +800.9%
Vaxart, Inc.
$90M · P/E 2.8x · Buy
HIND +441.9%
Vyome Holdings, Inc.
$11M · P/E 0.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AEON, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Lake Street - Reiterated
Buy → Buy 2026-10-01 27% win rate (11 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-14 31% win rate (48 calls)
Lake Street ● Initiated
Buy 2026-07-30 27% win rate (11 calls)
Aegis Capital reit
Buy → Buy 2025-10-08 Building track record
HC Wainwright & Co. reit
Buy → Buy 2024-10-01 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2024-08-14 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-07-10 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
41
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →